Academic Journals Database
Disseminating quality controlled scientific knowledge

Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain

ADD TO MY LIST
 
Author(s): Melemedjian Ohannes | Asiedu Marina | Tillu Dipti | Sanoja Raul | Yan Jin | Lark Arianna | Khoutorsky Arkady | Johnson Jessica | Peebles Katherine | Lepow Talya | Sonenberg Nahum | Dussor Gregory | Price Theodore

Journal: Molecular Pain
ISSN 1744-8069

Volume: 7;
Issue: 1;
Start page: 70;
Date: 2011;
Original page

ABSTRACT
Abstract Neuropathic pain is a debilitating clinical condition with few efficacious treatments, warranting development of novel therapeutics. We hypothesized that dysregulated translation regulation pathways may underlie neuropathic pain. Peripheral nerve injury induced reorganization of translation machinery in the peripheral nervous system of rats and mice, including enhanced mTOR and ERK activity, increased phosphorylation of mTOR and ERK downstream targets, augmented eIF4F complex formation and enhanced nascent protein synthesis. The AMP activated protein kinase (AMPK) activators, metformin and A769662, inhibited translation regulation signaling pathways, eIF4F complex formation, nascent protein synthesis in injured nerves and sodium channel-dependent excitability of sensory neurons resulting in a resolution of neuropathic allodynia. Therefore, injury-induced dysregulation of translation control underlies pathology leading to neuropathic pain and reveals AMPK as a novel therapeutic target for the potential treatment of neuropathic pain.
RPA Switzerland

RPA Switzerland

Robotic process automation

    

Tango Rapperswil
Tango Rapperswil